Indian pharmaceutical market delivers flattish yoy growth in February 2022: Ind-Ra
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Amid a lower contribution from COVID-19 related drugs, credit rating agency, India Ratings and Research (Ind-Ra) in its latest report has showed that the Indian pharmaceutical market (IPM) delivered flattish year-on-year (yoy) growth in February 2022 against the strong 13.9% yoy growth reported in January 2022.
The report also highlighted flattish sales growth of the acute therapy segment compared to sub-chronic and chronic segments in February 2022. Ind-Ra noted that the acute therapy segment has been showing a robust performance since March 2021 (average growth at 22.7% yoy).
As per the report, post normalisation of the high growth months of April 2021 (51.5% growth) and May 2021 (47.8%), led by the lockdown related lower base last year and higher volume growth, the average IPM growth from June 2021 to February 2022 has been healthy (9.8% yoy). During February 2022, volumes declined by 7.3% yoy (January 2022: up 5.3% yoy), while price growth was 5.1% yoy (5.8% yoy) and new products launches were up 2.0% yoy (2.8% yoy).e
